Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Gene | SMARCB1 |
Variant | negative |
Impact List | unknown |
Protein Effect | loss of function |
Gene Variant Descriptions | SMARCB1 negative indicates a lack of the SMARCB1 gene, mRNA, and/or protein. |
Associated Drug Resistance | |
Category Variants Paths |
SMARCB1 mutant SMARCB1 inact mut SMARCB1 negative |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT05286801 | Phase Ib/II | Atezolizumab + Tiragolumab | Tiragolumab and Atezolizumab for the Treatment of Relapsed or Refractory SMARCB1 or SMARCA4 Deficient Tumors | Recruiting | USA | CAN | AUS | 0 |
NCT04416568 | Phase II | Ipilimumab + Nivolumab | Study of Nivolumab and Ipilimumab in Children and Young Adults With INI1-Negative Cancers | Recruiting | USA | 0 |
NCT03587662 | Phase II | Gemcitabine + Ixazomib Doxorubicin + Gemcitabine + Ixazomib | Ixazomib, Gemcitabine, and Doxorubicin in Treating Patients With Locally Advanced or Metastatic Kidney Cancer | Active, not recruiting | USA | 0 |
NCT05407441 | Phase Ib/II | Ipilimumab + Nivolumab + Tazemetostat | Tazemetostat+Nivo/Ipi in INI1-Neg/SMARCA4-Def Tumors | Recruiting | USA | 0 |
NCT05347212 | Phase II | Nivolumab + Relatlimab | Phase II Trial of Immunotherapy in Patients With Carcinomas Arising From the Renal Medulla | Active, not recruiting | USA | 0 |